Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + diphenhydramine + montelukast + methylprednisolone
- Development stage
- Unknown
- Lead developer
- NYU Langone Health
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a pre-medication regimen administered 1-3 hours before the subcutaneous injection of daratumumab and hyaluronidase-fihj (Darzalex Faspro) to reduce the risk of infusion-related reactions (IRRs). The regimen consists of an analgesic/antipyretic (acetaminophen), an H1-receptor antagonist (diphenhydramine), a leukotriene receptor antagonist (montelukast), and a corticosteroid (methylprednisolone). This specific combination is utilized in a Phase 2 clinical trial conducted by NYU Langone Health for patients with STK11/LKB1 mutated non-small cell lung cancer (NSCLC). The components work synergistically to mitigate hypersensitivity and inflammatory responses triggered by the monoclonal antibody therapy.
- Other names
- Pre-Intervention MedicationPre-medication for Darzalex Faspro
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on acetaminophen + diphenhydramine + montelukast + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + diphenhydramine + montelukast + methylprednisolone.